메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Daewoong Pharmaceutical: Third IDMC Reaffirms Safety of Ber…

Third Independent Data Monitoring Committee (IDMC) review confirms safety and continuation of the study 94 patients enrolled out of 102 planned across Korea and the U.S. Interim baseline characteristics to be presented at the 2025 KATRD International Conference SEOUL, South Korea, Oct. 27, 2025 -- Daewoong Pharmaceutical (Co-CEOs Seong-Soo Park and Chang-Jae Lee) announced that its first-in-class idiopathic pulmonary fibrosis (IPF) drug candidate Bersiporocin (DWN12088) received a recommendation to continue its global Phase 2 clinical trial following a positive safe
- 김갑성 기자
- 2025-10-27 19:00
Ascletis to Present Study Results of ASC30 Oral Tablet, ASC30 Inje…

[ 메디채널 김갑성 기자 ] -Multiple posters being presented on Ascletis' small molecule and peptide obesity programs -Full analysis of 28-day multiple ascending dose study of oral GLP-1R small molecule agonist ASC30 as a late-breaking poster as well as ASC30 once-monthly treatment formulation and once-quarterly maintenance formulation HONG KONG, Oct. 27, 2025 -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces multiple poster presentations of its obesity assets including ASC30, and combination of ASC31 and ASC47 at ObesityWeek® 2025 in Atlanta, Georgia. Prese
- 김갑성 기자
- 2025-10-27 18:00
MINISH Technology Has Successfully Concluded Its First U.S.…

SEOUL, South Korea, Oct. 27, 2025 -- Health-tech company MINISH Technology Inc. announced on the 27th that 22 dentists completed its 15th MINISH Course, the first session held for local practitioners in the United States. The three-day course was held from October 24 to 26 at the VITA North America training center in Orange County, California, as an officially recognized Continuing Education (CE) program for dental professionals in the United States. Although tuition fees were nearly 50% higher than comparable local programs, the course sold out quickly, demonstrating strong in
- 김갑성 기자
- 2025-10-27 14:58
Raffles Medical Group Partners Gene Solutions to Expand Ac…

SINGAPORE, Oct. 27, 2025 -- Raffles Medical Group (the Group) and Gene Solutions have signed a Memorandum of Understanding (MOU) on 22 October 2025 to streamline patient recruitment for oncology clinical trials, marking a significant milestone in advancing precision medicine in Southeast Asia. Under this partnership, the Group and Gene Solutions will collaborate to identify patients eligible for pharma-sponsored clinical trials. Patients undergoing Comprehensive Genomic Profiling (CGP) via Gene Solutions will be automatically screened for eligibility. The Group's Clinical Trials Unit w
- 김갑성 기자
- 2025-10-27 13:22
KLN Named Exclusive Distributor for Siemens Healthineers

[ 메디채널 김갑성 기자 ] Point-of-Care Testing Solutions in Hong Kong HONG KONG, Oct. 27, 2025 -- KLN Logistics Group Limited ('KLN'; Stock Code 0636.HK) announces a strategic partnership between its healthcare subsidiary, KLN Medical Limited ('KLN Medical'), and global medical technology leader Siemens Healthineers AG (Stock Code SHL.DE). KLN Medical will serve as the exclusive distributor for Siemens Healthineers' Point-of-Care Testing products in Hong Kong. This partnership marks a major milestone for KLN Medical as it expands in life sciences sector. KLN Medical will provide end-to
- 김갑성 기자
- 2025-10-27 12:00
Alphamab Oncology Announces Biparatopic HER2-targeting…

SUZHOU, China, Oct. 27, 2025 -- Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to initiate a Phase III clinical study (Study ID: JSKN003-005) for the treatment of HER2-positive advanced colorectal cancer (CRC). This marks
- 김갑성 기자
- 2025-10-27 09:51
Antengene Presents Latest Preclinical Data of ATG-201 (CD19 x…

SHANGHAI and HONG KONG, Oct. 27, 2025 -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the latest preclinical data of ATG-201 (CD19 x CD3 TCE) were presented in a Poster Presentation at the 2025 American College of Rheumatology (ACR) Annual Meeting, taking place from October 24th to October 29th in
- 김갑성 기자
- 2025-10-27 09:00
Innovent's Mazdutide Shows Superiority in Glycemic Control w…

[ 메디채널 김갑성 기자 ] The proportion of participants achieving HbA1c < 7.0% and a ≥10% reduction in body weight from baseline was 48.0% in the mazdutide group and 21.0% in the semaglutide group DREAMS-3 is the world's first Phase 3 clinical trial of a GCG/GLP-1 dual receptor agonist to conduct a head-to-head comparison with semaglutide in diabetes treatment SAN FRANCISCO and SUZHOU, China, Oct. 27, 2025 -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for th
- 김갑성 기자
- 2025-10-27 08:00
Real-World Data Presented at TCT 2025 Demonstrates the Egg…

SAN FRANCISCO, Oct. 26, 2025 -- At the 2025 Transcatheter Cardiovascular Therapeutics® (TCT) Conference, Dr. Jarrod Frizzell of The Christ Hospital (Cincinnati, OH) presented real-world studies¹,² demonstrating that the EggNest™ Complete Radiation Protection System from Egg Medical, Inc. (Roseville, MN) dramatically reduces radiation exposure for all members of the interventional team — including physicians, nurses, and technologists — compared to traditional shielding methods. During X-ray–guided cardiovascular procedures, scatter radiation poses a well-documented occup
- 김갑성 기자
- 2025-10-27 01:00
WuXi AppTec Achieves Strong Double-Digit Growth in Revenue…

Q3 Total Revenue: RMB12.06 Billion, Up 15.3% YoY; Revenue from Continuing Operations[1] Reached RMB12.04 Billion, Up 19.7% YoY Q1-Q3 Total Revenue: RMB32.86 Billion, Up 18.6% YoY; Revenue from Continuing Operations Reached RMB32.45 Billion, Up 22.5% YoY Q1-Q3 Net Profit Attributable to Owners of the Company Reached RMB12.08 Billion[2], Up 84.8% YoY; Diluted Earnings per Share (EPS) of RMB4.21[3], Up 87.9% YoY Q1-Q3 Adjusted Non-IFRS Net Profit Attributable to the Owners of the Company Reached RMB10.54 Billion, Up 43.4% YoY;
- 김갑성 기자
- 2025-10-26 15:53

이전

51 52 53 54 55 56 57 58 59 60

많이 본 기사

최근기사

2025-12-13_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 13일 20시 40분